Submissions from 2020
Efficacy and safety of switching to tenofovir alafenamide (TAF) in virally-suppressed chronic hepatitis B patients (CHB) with renal impairment: Week 24 results, C W. Long, H Yi-Hsiang, L Young-Suk, J G. Edward, A S. Hoon, T TY Owen, H Jeong, H A. Josun, E Magdy, C Chi-Yi, S Wei-Wen, F John, G Anuj, Y J. Leland, S Shalini, J Belinda, M Shuyuan, Syed-Mohammed Jafri, and L AJ Harry
IMPACT OF HISTORY OF CHRONIC VIRAL HEPATITIS AND LIVER FIBROSIS ON RISK OF HOSPITALIZATION AND DEATH AMONG PATIENTS WITH SARS-COV-2 INFECTION, Mei Lu, Loralee B. Rupp, J A. Boscarino, M A. Schmidt, Y Daida, Yueren Zhou, Sheri Trudeau, Jia Li, and Stuart C. Gordon
LIVER TRANSPLANT EVALUATION IN THE PETH ERA, Sandra Naffouj, Ranya Selim, Omar Shamaa, Abdelwahab Ahmed, Yueren R. Zhou, Loralee B. Rupp, Syed M. Jafri, Stuart C. Gordon, and Humberto C. Gonzalez
THE IMPLICATIONS OF CHRONIC OPIOID USE ON POST-TRANSPLANT CLINICAL OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS, Sandra Naffouj, Mohammad A. Siddiqui, Amna Shaikh, Nawal Shabbir, Aimun Shabbir, and Reena J. Salgia
USE OF NEURAL NETWORK MODELS TO PREDICT MORTALITY/ SURVIVAL AMONG PATIENTS ON THE LIVER TRANSPLANT WAITLIST, Shunji Nagai, Anubhav Reddy Nallabasannagari, Dilip Moonka, Madhu Reddiboina, Michael Nanna, Lucy Chau, Sirisha Yeddula, Toshihiro Kitajima, Iman Bajjoka-Francis, and Marwan S. Abouljoud
960 Maximizing success in single-session edge - predictive factors of stent migration, B Shinn, T Boortalary, I Raijman, J Nieto, H S. Khara, S V. Kumar, B Confer, D L. Diehl, M AAN El Halabi, Y Ichkhanian, T M. Runge, V Kumbhari, M A. Khashab, A Tyberg, H M. Shahid, A Sarkar, M Gaidhane, R Bareket, M Kahaleh, Cyrus Piraka, Tobias Zuchelli, R Law, A R. Sondhi, P Kedia, J S. Robbins, C Calogero, M Bakhit, A L. Chiang, A Schlachterman, T E. Kowalski, and D E. Loren
LIVER INJURY IS ASSOCIATED WITH INCREASED MORBIDITY AND MORTALITY IN COVID-19 PATIENTS, Mohammad A. Siddiqui, Suraj Suresh, Mouhanna Abu Ghanimeh, Megan Karrick, Faisal M. Nimri, Maher Musleh, Vivek Mendiratta, Mustafa Al-Shammari, Stephen Simmer, Jessica Jou, Sarah Russell, Duyen Y. Dang, Reena J. Salgia, and Tobias Zuchelli
CLINICAL OUTCOMES IN HOSPITALIZED COVID-19 PATIENTS WITH CHRONIC LIVER DISEASE AND CIRRHOSIS, Suraj Suresh, Mohammad Siddiqui, Mouhanna Abu Ghanimeh, Faisal M. Nimri, Megan Karrick, Maher Musleh, Vivek Mendiratta, Sarah Russell, Jessica Jou, Stephen Simmer, Mustafa Al-Shammari, Duyen Dang, and Tobias Zuchelli
Accuracy of agitated saline contrast echocardiography for assessment of intracardiac shunting in preoperative liver transplant patients, Benjamin Swanson, Reena Salgia, Jaber El-Bashir, and Sachin Parikh
Recurrence rate and risk factors following cold snare endoscopic mucosal resection of polyps ≥20 mm in size, Jinyu Zhang, Suraj Suresh, Abdelwahab Ahmed, Cyrus Piraka, Mouhanna Abu Ghanimeh, Robert Pompa, Sumit Singla, Duyen Dang, Mahmoud Isseh, Ahmed Elbanna, Randeep Kaur, and Tobias Zuchelli
Submissions from 2019
170 Post ERCP de novo fever and de novo bacteremia: Insights from the national inpatient database, A Bhurwal, H R. Mutneja, Khwaja F. Haq, M Bartel, and B Brahmbhatt
The Treatment of Hepatitis C Virus (HCV) with Direct Acting Antiviral (DAA) Treatment in the Post Orthotopic Liver Transplant (OLT) Patient Is Safe and Efficacious, P Brown, Zachary Demertzis, and Syed-Mohammed Jafri
Predictors and Outcomes of Acute Graft-Versus-Host Disease After Liver Transplant, Allyce Caines, Shunji Nagai, and Reena Salgia
Prediction of delayed graft function in combined liver-kidney transplantation: An analysis using the UNOS registry, Lucy Chau, M Safwan, Dilip Moonka, Dean Kim, Atsushi Yoshida, Marwan S. Abouljoud, and Shunji Nagai
Sofosbuvir/Velpatasvir Is Effective and Safe in Patients with Concomitant Proton PUMP Inhibitor Use in Clinical Studies, C Cooper, K Agarwal, J L. Calleja, J F. Dufour, S L. Flamm, Stuart C. Gordon, L Stamm, L Ni, D Brainard, A A. Cumaraswamy, K Kowdley, R Esteban, J A. Pineda, L Castells, M Buti, and S Lens
Sofosbuvir/Velpatasvir is effective and safe in patients with concomitant proton pump inhibitor use in clinical studies., R Esteban, K Agarwal, C L. Jose, F J. Dufour, S L. Flamm, Stuart C Gordon, W Y. Lu, C Lu, L Stamm, Y L. Ni, D Brainard, K V. Kowdley, C Cooper, P A. Juan, L Castells, M Buti, and S Lens
Evaluation of Liver Transplantation Among Advanced Age Recipients in a Large Multicenter U. S. Cohort, A Goel, A Kwong, D Devuni, C Wang, J Boike, J Jo, L Van Wagner, M Serper, L Jones, R Sharma, E Vema, J Shor, M German, A Hristov, A Lee, E Slengler, A Koteish, G Sehmbey, A Seetharam, N John, Y Patel, M Kappus, T Couri, Reena Salgia, Q Nhu, C Frenette, and J Lai
More than 4 times higher healthcare costs for end-stage liver disease patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, Stuart C. Gordon, N Kachru, S Sanatan, D Martinez, M Moynihan, and R Wong
Substantial healthcare utilization (HCU) and costs among nonalcoholic steatohepatitis (NASH) patients with comorbid diabetes mellitus (DM): Real-world analysis of 2007-2015 US medicare data., Stuart C Gordon, S Li, Y Peng, X Wang, and R Wong
Fibrosis-4 score (FIB-4) provides consistent assessment of healthcare costs and healthcare resource utilization (HCRU) among Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) patients with advanced fibrosis., Stuart C. Gordon, B Ozbay, E Parker, S Korrer, and R Wong
PIN26 Cost-minimization analysis of pan-genotypic treatment regimens for chronic hepatitis C, Stuart C. Gordon, N Smith, and D Dieterich
Inadequate response to UDCA among PBC patients under routine care in the US: Rising serum bilirubin even in the normal range is a risk factor and subsequent clinical follow-up differs based on treatment response, Stuart C. Gordon, Talan Zhang, C L. Bowlus, K D. Lindor, R J. Romanelli, I V. Haller, H Anderson, J J. Vanwormer, J A. Boscarino, M A. Schmidt, Y G. Sahota, J Vincent, Kuan-Han Wu, Sheri Trudeau, Christina Melkonian, Loralee B. Rupp, and Mei Lu
Effect of treatment of hepatitis B patients with tenofovir disoproxil or entecavir on risk of hepatocellular cancer death in a U.S. Cohort, Stuart C. Gordon, Yueren Zhou, Jian Li, Loralee B. Rupp, J A. Boscarino, Y G. Daida, M A. Schmidt, Sheri Trudeau, and Mei Lu
Molecular analysis of rejection and injury in liver transplant biopsies: The INTERLIVER STUDY, P Halloran, A Montano-Loza, Marwan S. Abouljoud, Dilip Moonka, T Reichman, G McCaughan, M Myslak, K Jurczyk, K Zieniewicz, M Grat, and A Perkowska-Ptasiμ Ska
An Unusual Case of Bleeding Gastric Varices Secondary to Metastatic Ovarian Adenocarcinoma, Randeep Kaur, Reena Salgia, Crystal Seudeal, and Eric Scher
Patients with Biliary Complications Following Orthotopic Liver Transplantation Can Be Successfully Managed by Serial Endoscopic Retrograde Cholangio-Pancreatography, R Kaur, I C. Morales, Dilshan Dhillon, M S. Ilias, Shunji Nagai, Deepak Venkat, Atsushi Yoshida, and Syed-Mohammed Jafri
Monitoring and Management of Proteinuria Is Often Ignored in Patients Receiving mTOR Therapy Following Orthotopic Liver Transplantation, R Kaur, Omar Sadiq, Maryam Alimirah, F Kumssa, A Patel, and Syed-Mohammed Jafri
Correlation Between Bilirubinemia and Acute Kidney Injury in Patients with Cirrhosis, Adrienne Lenhart, P Brown, Omar Khan, Maryam Alimirah, Hafsa Abdulla, Reena Salgia, and Junior Uduman
Complications of chronic hepatitis B: Prevalence and disparities in a US health system cohort 2006-2016, Mei Lu, Yueren Zhou, Jian Li, Loralee B. Rupp, J A. Boscarino, Y G. Daida, M A. Schmidt, Sheri Trudeau, and Stuart C. Gordon
Seladelpar for the treatment of primary biliary cholangitis: Experience with 26 cirrhotic patients, M J. Mayo, C Bowlus, G Michael, G Neff, P Trivedi, A Goel, J Odin, B Bacon, B Borg, Stuart C. Gordon, A Gulamhusein, S Harrison, C Levy, C Stanca, J Vierling, A Steinberg, M Varga, J Nguyen, S Bergheanu, Y J. Choi, M Standen, and P Boudes
Extreme hyponatremia as a risk factor for early mortality after liver transplantation in the model for end-stage liver disease-sodium period, H Mouzaihem, M Safwan, L Chau, Marwan Abouljoud, Dilip Moonka, and Shunji Nagai
Share 21 Rather Than Share 15: Balancing Transplant Opportunity Without Compromising Waitlist Outcomes, Shunji Nagai, Lucy Chau, Marwan S. Abouljoud, Kelly Collins, Syed-Mohammed Jafri, M Safwan, and Dillip Moonka
Patients with non-alcoholic steatohepatitis have inferior liver transplant outcomes, Shunji Nagai, Kelly Collins, Lucy C. Chau, Michael D. Rizzari, Atsushi Yoshida, Marwan S. Abouljoud, M Safwan, and Dillip Moonka
Effects of major liver allocation policy changes on waitlist outcomes in multivisceral transplantation in the United States, Shunji Nagai, Yakir Muszkat, Michael Rizzari, Syed-Mohammed Jafri, and Marwan Abouljoud
Effects of Major Liver Allocation Policy Changes on Waitlist Outcomes in Multivisceral Transplantation, Shunji Nagai, Michael Rizzari, Yakir Muszkat, Kelly Collins, Atsushi Yoshida, Syed-Mohammed Jafri, and Marwan Abouljoud
Fatal Graft Versus Host Disease in Liver Transplantation: An Analysis of UNOS Registry, Shunji Nagai, Atsushi Yoshida, Reena Salgia, Marwan Abouljoud, and Dilip Moonka
A National Survey of Immunosuppression Strategies in Intestinal Transplantation, M C. Segovia, T Beduschi, J Boike, D Farmer, S Horslen, K Iyer, Syed-Mohammed Jafri, A Langnas, C Matsumoto, A Mavis, G Mazariegos, Shunji Nagai, J O'Leary, Y Patel, D Sudan, Nimisha Sulejmani, Bryant B. Summers, and T Schiano
A Multicenter Study of mTor Inhibitor Use in Intestine and Multivisceral Transplantation, M C. Segovia, A Mavis, J Boike, Y Patel, T Schiano, and Syed-Mohammed Jafri
Safety and efficacy of mTOR inhibitors following intestine and multivisceral transplantation, M C. Segovia, D Sudan, Shunji Nagai, Yakir Muszkat, A Mavis, T Schiano, and Syed-Mohammed Jafri
Perioperative Lactate Levels Are Sensitive Marker to Predict Early Allograft Dysfunction and Short-Term Graft Failure After Liver Transplant, K Takahashi, Shunji Nagai, Kelly Collins, Michael Rizzari, M Safwan, Syed-Mohammed Jafri, T Oda, Atsushi Yoshida, and Marwan S. Abouljoud
Management of Anastomotic Biliary Strictures After Liver Transplant: Role of Covered Metal Stents, Andrew Watson, Khwaja F. Haq, Kamal Khorfan, Sumit Singla, Atsushi Yoshida, and Dilip Moonka
Rising and higher healthcare-resource-utilization (HCRU) and costs of Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH) patients with advanced liver disease-a US real-world-analysis., R Wong, N Kachru, N Meyer, and Stuart C Gordon
Submissions from 2018
The roles of therapeutic plasmapheresis (TPE) and extracorporeal photopheresis (ECP) for the treatment of liver allograft rejection., Beena U. Ahsan, A Eisenbrey, Mohammad Raoufi, Dilip Moonka, and Ileana Lopez-Plaza
Effect of SVR on liver-related and all-cause hospitalization of patients with chronic HCV infection: The chronic hepatitis cohort study (CHECS), 2014-16., R Augustine, J Xing, P R. Spradling, A C. Moorman, Loralee B. Rupp, Stuart C. Gordon, Mei Lu, J A. Boscarino, M A. Schmidt, Y Daida, S D. Holmberg, and E H. Teshale
Efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis: 52-week analysis of an ongoing international, randomized, dose ranging phase 2 study., C L. Bowlus, G Neff, R Aspinall, Michael R. Galambos, A Goel, Gideon M. Hirschfield, Andreas E. Kremer, M J. Mayo, Mark G. Swain, B Borg, Y Dorffel, Stuart C. Gordon, S Harrison, D Jones, Paul J. Thuluvath, C Levy, D AS Heridan, C Stanca, Bruce R. Bacon, B Berg, Tarek Hassanein, J Odin, Mitchell L. Shiffman, D Thorburn, John M. Vierling, David Bernstein, Peter Buggisch, Linsey Corless, Charles S. Landis, A L. Peyton, Shah H. A, M A. Woerns, Norman Gitlin, A Steinberg, S Bergheanu, Chad Amato, G Amato, Yun-Jung Choi, S Rosenbusch, M Varga, Charles A McWherter, and P Boudes
International multicenter study on digital single operator pancreatoscopy for the management of pancreatic stones., O I. Brewer Gutierrez, I Raijman, B J. Elmunzer, G Webster, D K. Pleskow, S Sherman, R Sturgess, D V. Sejpal, C Ko, A Maurano, D G. Adler, Daniel Mullady, D S. Strand, C J. DeMaio, Cyrus Piraka, R Z. Sharaiha, M Dbouk, S Han, C Spyceland, N Bekkali, M Gabr, B L. Bick, L K. Dwyer, D Han, J Buxbaun, C Zulli, N Cosgrove, A Y. Wang, D L. Carr-Locke, T Kerdsirichairat, H Aridi, R Moran, S Shah, J Yang, O Sanaei, Davinder Parsad, N Parsa, V Kumbhari, V Singh, and M A. Khashab
One-year outcomes in patients with advanced liver fibrosis or compensated cirrhosis from chronic hepatitis C receiving kidney transplant alone., P Brown, Fitsum Kumssa, and Deepak Venkat
Elbasvir-grazoprevir (Zepatier) is effective and safe for the treatment of chronic hepatitis C (HCV) genotype 1 virus in the post kidney transplant patient. Am J Transplant 2018; 18:941., P Brown and Deepak Venkat
Regional variation in the outcomes of meld-na based liver allocation., Lucy Chau, Dilip Moonka, Kelly Collins, Michael Rizzari, Atsushi Yoshida, Marwan S. Abouljoud, and Shunji Nagai
Sofosbuvir/velpatasvir is effective and safe in patients with concomitant proton pump inhibitor use in clinical studies, R Esteban, K Agarwal, Jose L Calleja, Jean-Francois Dufour, Steven L Flamm, L Ni, Stuart C Gordon, L Stamm, D Brainard, K V Kowdley, C Cooper, J A. Pineda, L Castells, M Buti, and S Lens
Increasing healthcare resource utilization (HCRU) and costs associated with advanced liver disease-a multivariate analyses of real-world medicare nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/ NASH) patients., Stuart C. Gordon, Jeremy Fraysse, L Li, and Richard J. Wong
Comparative analysis of direct-acting antiviral regimens across Hepatitis C genotypes and clinical characteristics among patients under routine clinical care in the US., Stuart C. Gordon, S D. Holmberg, A C. Moorman, P R. Spradling, E H. Teshale, J A. Boscarino, Y Daida, M A. Schmidt, Kuan-Han Wu, Loralee B. Rupp, Talan Zhang, Sheri Trudeau, and Mei Lu
Substantial healthcare utilization (HCU) and costs among nonalcoholic steatohepatitis (NASH) patients with comorbid diabetes mellitus (DM): Real-world analysis of 2007-2015 US Medicare data., Stuart C. Gordon, S Li, Y Peng, X Wang, and R Wong
Fibrosis-4 score (FIB-4) provides consistent assessment of healthcare costs and healthcare resource utilization (HCRU) among nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients with advanced fibrosis., Stuart C Gordon, B Ozbay, E Parker, S Korrer, and Richard J Wong
Serum bilirubin within normal range is associated with an increasing risk of mortality in patients with primary biliary cholangitis regardless of ursodeoxycholic acid treatment. Hepatology 2018; 68:31A-32A., Stuart C. Gordon, C Rodriguez, R J. Romanelli, I V. Haller, H Anderson, J J. VanWormer, J A. Boscarino, M A. Schmidt, Y Daida, A K. Sahota, J L. Vincent, C L. Bowlus, Talan Zhang, Sheri Trudeau, J Li, Christina Melkonian, Kuan-Han Wu, Loralee B. Rupp, and Mei Lu
Effect of seladelpar on pruritus in primary biliary cholangitis: 26-week analysis of an ongoing international, randomized, dose ranging phase 2 study. Hepatology 2018; 68(1):1464A-1465A., Andreas E. Kremer, C L. Bowlus, G Neff, R Aspinall, Michael R. Galambos, A Goel, Gideon M. Hirschfield, M J. Mayo, Mark G. Swain, B Borg, Y Dorffel, Stuart C. Gordon, S A. Harrison, D Jones, Paul J. Thuluvath, John M. Vierling, D Bernstein, Peter Buggisch, Linsey Corless, C SL Andis, A L. Peyton, H A. Shah, M A. Woerns, Norman Gitlin, A Steinberg, S Bergheanu, G Amato, Yun-Jung Choi, S Rosenbusch, M Varga, Charles A. McWherter, and P Boudes
Safety and efficacy of treatment with once-daily ledipasvir/sofosbuvir (90/400 mg) for 12 weeks in genotype 1 hcv-infected patients with severe renal impairment., Eric Lawitz, Charles S Landis, Benedict Maliakkal, M Bonacini, G Ortiz-Lasanta, J Zhang, E Mogalian, S De-Oertel, Anu Osinusi, Diana M Brainard, John G McHutchison, CSM Yip, HC Huang, Steven L Flamm, Stuart C Gordon, and Edward J Gane
Epidemiological trends of chronic hepatitis b among routine clinical care patients in the US (2006-2015)., Mei Lu, Jia Li, S D. Holmberg, A C. Moorman, P R. Spradling, E H. Teshale, J A. Boscarino, Y Daida, M A. Schmidt, Yueren Zhou, Loralee B. Rupp, Talan Zhang, Sheri Trudeau, and Stuart C. Gordon
Hepatitis C patients with HIV co-infection demonstrate unique liver-related complications and health behaviors compared to HCV mono-infected patients., Mei Lu, Norman Markowitz, Yueren Zhou, Kuan-Han H. Wu, Loralee B. Rupp, Sheri Trudeau, J A. Boscarino, M A. Schmidt, Y G. Daida, and Stuart C. Gordon
HIV co-infection is associated with increased liver complications and reduced mental health among patients with chronic hepatitis B., Mei Lu, Norman Markowitz, Yueren Zhou, Kuan-Han H. Wu, Loralee B. Rupp, Sheri Trudeau, J A. Boscarino, M A. Schmidt, Y G. Daida, and Stuart C. Gordon
The safety and tolerability of sof/vel/vox for 8 or 12 weeks in > 1,000 patients treated in the polaris-1, polaris-2, polaris-3, and polaris-4 studies: An integrated analysis., Michael P. Manns, Edward Gane, B E. Willems, Stuart K. Roberts, S L. Flamm, Marc Bourliere, Tarik Asselah, L Alric, Robert H. Hyland, Luisa M. Stamm, K C. Huang, Diana M. Brainard, C SM Yip, H C. Huang, M Khalili, Graham R. Foster, Stuart C. Gordon, R K. Rajender, Stefan Zeuzem, Ira M. Jacobson, Curtis L. Cooper, A J. Thompson, K V. Kowdley, and Eric Lawitz
Factors influencing post-transplant mortality in primary biliary cholangitis., Vivek Mendiratta, K Alsafadi, and Deepak Venkat
Predictors of hepatic encephalopathy in cirrhotic patients undergoing elective transjugular intrahepatic portosystemic shunt, Vivek Mendiratta, Fitsum Kumssa, and Deepak Venkat
Albumin and age as independent predictors of 1 year mortality in cirrhotic patients undergoing elective tips., Vivek Mendiratta, Kajali Mishra, H Abdulla, and Deepak Venkat
The impact of spontaneous bacterial peritonitis on patient outcomes after liver transplantation using the scientific registry of transplant recipient (SRTR) database, Dillip Moonka, George W. Divine, and Shunji Nagai
Presence of advanced liver disease concurrent with initial diagnosis of Hepatitis C virus (HCV) infection among patients in the chronic hepatitis cohort study (CHECS) 2014-16: Missed opportunities for intervention., A C. Moorman, J Xing, Loralee B. Rupp, Stuart C. Gordon, Mei Lu, P R. Spradling, J A. Boscarino, Y Daida, M A. Schmidt, S D. Holmberg, and E H. Teshale
MELD-Na score based liver allocation: Hyponatremia is no longer a risk factor for waitlist mortality., Shunji Nagai, Lucy Chau, Mohamed Safwan, Randolph E. Schilke, Michael Rizzari, Kelly Collins, Atsushi Yoshida, Marwan Abouljoud, and D Moonka
Survival benefit of liver transplantation in the MELD-Na era., Shunji Nagai, Lucy Chau, M Safwan, R Schilke, Michael Rizzari, Kelly Collins, Atsushi Yoshida, Marwan S. Abouljoud, and Dilip Moonka
Comparison of induction and maintenance immunosuppression regimens in intestinal and multivisceral transplantation: An analysis of the unos registry., Shunji Nagai, Michael Rizzari, Yakir Muszkat, Kelly Collins, Atsushi Yoshida, Syed-Mohammed Jafri, and Marwan S. Abouljoud
Hidden risk of liver transplantation for nonalcoholic steatohepatitis: A propensity score matched study., Shunji Nagai, R Schilke, M Safwan, Michael Rizzari, Kelly Collins, Atsushi Yoshida, Marwan S. Abouljoud, and D Moonka
Delayed early lactate clearance after liver transplantation: A propensity score matching study., Shunji Nagai and K Takahashi
SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 weeks in DAA-naive patients: An integrated analysis of the POLARIS-1 POLARIS-2, POLARIS-3 and POLARIS-4 studies., Stuart K. Roberts, Curtis L. Cooper, Eric Lawitz, Rajender Reddy, A J. Thompson, Stefan Zeuzem, Ira M. Jacobson, P Ruane, Robert H. Hyland, Luisa M. Stamm, L Han, D M. Brainard, C SM Yip, H C. Huang, N Brau, T Asselah, B E. Willems, S Flamm, M Bourliere, G R. Foster, E J. Gane, M Manns, Stuart C. Gordon, and K Kowdley
Opiate use trends after liver transplantation and the factors associated with post-transplant opiate dependence., Mohammad A. Siddiqui, R Kaur, S Dhoop, Nimisha Sulejmani, and Reena Salgia
Direct-acting antiviral therapy significantly reduces early HCC recurrence: A multicenter u.s. cohort study., A G. Singal, N Mehta, N E. Rich, C Murphy, A D. Branch, A A. Pillai, M A. Hoteit, M Volk, M Odewole, S J. Scaglione, J E. Guy, A Said, J J. Feld, B John, C T. Frenette, P S. Mantry, A S. Rangnekar, O Oloruntoba, M D. Leise, J Jou, K R. Bhamidimarri, L M. Kulik, T T. Tran, H V. Samant, R Dhanaskekaran, A Duarte-Rojo, Reena Salgia, S L. Eswaran, A A. Modi, A Flores, S K. Satapathy, R J. Wong, A Huang, S Misra, ME Schwartz, R Mitrani, CK Ho, S Sharma, VR Konjeti, A Dao, K Nelson, M Gulau, K Delarosa, U Rahim, M Mavuram, JJ Xie, and ND Parikh
Severe liver disease outcomes and mortality among patients with chronic hepatitis B who completed an in-depth health and behavior survey in 2012, P R. Spradling, J Xing, A C. Moorman, Loralee B. Rupp, Stuart C. Gordon, J A. Boscarino, M A. Schmidt, Y Daida, Mei Lu, E H. Teshale, and S D. Holmberg
Setting minimum standards for training in EUS and ERCP: Results from a prospective multicenter study evaluating learning curves and competence among advanced endoscopy trainees (AETS)., S B. Wani, S Han, V C. Simon, M Hall, D Early, E Aagaard, L Carlin, S Ellert, W M. Abidi, T H. Baron, B C. Brauer, H Chatrath, G A. Cote, K K. Das, C J. DiMaio, S A. Edmundowicz, I I. El Hajj, H T. Hammad, S Jalaj, M L. Kochman, S Komanduri, L S. Lee, D Mullady, V Raman Muthusamy, A S. Nett, M S. Olyaee, K Pakeresht, P Perera, P Pfau, Cyrus Piraka, A Rastogi, R J. Shah, R Sharma, JM Scheiman, JH Tabibian, D Uppal, S Urayama, AY Wang, Tobias Zuchelli, E Bowman, G Lang, DE Loren, AH El Chafic, P Yachimski, A Gamboa, JM Poneros, W Wassef, M Sohail, T Stevens, B Confer, NM Guda, S Ian Gan, A Razzak, Stuart C Gordon, J Ferriera, S Banerjee, A Choudhary, AM Dries, JM Buscaglia, D Tzimas, S Zepeda-Gomez, S Kenshil, F Lukens, M Bartel, P Jowell, JP Spaete, B Riff, C Harris, S Saligram, B Gannavarapu, A Chak, A Singh, and RN Keswani
A prospective multicenter study evaluating EUS and ERCP competence during advanced endoscopy training and subsequent independent practice: The rapid assessment of trainee endoscopy skills (rates2) study., S B. Wani, R N. Keswani, M Hall, S Han, E Aagaard, V C. Simon, L Carlin, S Ellert, W M. Abidi, T H. Baron, B C. Brauer, H Chatrath, G A. Cote, K K. Das, C J. DiMaio, S A. Edmundowicz, I I. El Hajj, H T. Hammad, S Jalaj, M L. Kochman, S Komanduri, L S. Lee, D Mullady, V Raman Muthusamy, A S. Nett, M S. Olyaee, K Pakeresht, P Perera, P Pfau, Cyrus Piraka, A Rastogi, R J. Shah, R Sharma, JM Scheiman, JH Tabibian, D Uppal, S Urayama, AY Wang, Tobias Zuchelli, E Bowman, G Lang, DE Loren, AH El Chafic, P Yachimski, A Gamboa, JM Poneros, W Wassef, M Sohail, T Stevens, B Confer, NM Guda, S Ian Gan, A Razzak, SR Gordon, J Ferriera, S Banerjee, A Choudhary, AM Dries, JM Buscaglia, D Tzimas, S Zepeda-Gomez, S Kenshil, F Lukens, M Bartel, P Jowell, JP Spate, B Riff, C Harris, S Saligram, B Gannavarapu, A Chak, A Singh, and D Early
Repair of upper gastrointestinal fistulas and anastomotic leakage utilizing endoluminal vacuum-assisted closure., Andrew Watson and Tobias Zuchelli
Rising and higher healthcare resource utilization (HCRU) and costs of nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) patients with advanced liver disease of increasing severity-results of a US real-world analysis., Richard J. Wong, N Kachru, N Meyer, and Stuart C. Gordon
Retreatment of hepatitis C infection in patients who failed glecaprevir/pibrentasvir., D L. Wyles, O Weiland, B Yao, R Reindollar, F Weilert, J F. Dufour, Stuart C. Gordon, F Poordad, A Stoehr, A Brown, S Mauss, S Samanta, T Pilot-Matias, L Rodrigues, and R Trinh
Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection., D Wyles, O Weiland, B Yao, R Reindollar, F Weilert, J F. Dufour, Stuart C. Gordon, F Poordad, A Stoehr, A Brown, S Mauss, S Samanta, T Pilot-Matias, L R. Jr, and R Trinh
Patient-reported outcomes in chronic hepatitis C: The impact of placebo, active treatment, and sustained viral eradication., Z Younossi, M Stepanova, M P. Manns, R Reddy, Stuart C. Gordon, and M Bourliere
Long-term follow up of patients with chronic HCV and F2 or F3 fibrosis after achieving SVR with DAA-based therapy: Results from the Gilead SVR registry., S Zeuzem, M B. Ferret, E Gane, I Jacobson, Stuart C. Gordon, M Sulkowski, B McNabb, F Chen, H Dvory-Sobol, A Osinusi, D Brainard, M Subramanian, A Ramji, K Agarwal, R Reddy, and M Bourliere
Submissions from 2017
Risk factors and outcomes of intracardiac thrombosis during orthotopic liver transplantation., Waleed Al-Darzi, Mazen M. El-Atrache, F Georgie, Omar Sadiq, Sumit Singla, C Fernandez, Robert Pompa, Dragos Galusca, Atsushi Yoshida, and Syed-Mohammed Jafri
Long-term follow up of patients with chronic HCV and no or minimal fibrosis shows low risk for liver-related morbidity and mortality after achieving SVR with DAA-based therapy: Results from the gilead SVR registry., M Bourlière, E J. Gane, I Jacobsen, Stuart C. Gordon, M S. Sulkowski, B L. McNabb, F Chen, H Dvory-Sobol, J McNally, D M. Brainard, M Subramanian, A Ramji, S Zeuzem, K Agarwal, and K R. Reddy
SOF/VEL/VOX for 12 weeks in NS5A-inhibitor experienced HCV-infected patients: Results of the deferred treatment group in the phase 3 POLARIS-1 study., M Bourlière, Stuart C. Gordon, E R. Schiff, T T. Tran, N Ravendhran, C S. Landis, R H. Hyland, J Zhang, H Dvory-Sobol, Luisa M. Stamm, D M. Brainard, J G. McHutchison, L Serfaty, A J. Thompson, T E. Sepe, M P. Curry, K R. Reddy, and M P. Manns
Cost-effectiveness analysis of first-line administration of tenofovir alafenamide (TAF), a novel nucleotide reverse transcrip-tase inhibitor (NRTI), for the management of chronic hepatitis b (CHB) in the united states (us)., Geoffrey Dusheiko, J Lim, I Liou, A Tafazzoli, B Deniz, C Saint-Laurent Thibault, Stuart C. Gordon, and M H. Nguyen
Health outcomes associated with sofosbuvir- based single-tablet regimens for initial and re-treatment of chronic hepatitis c in the US., Stuart C. Gordon, A Ahmed, S Saab, D T. Dieterich, R J. Wong, M Kugelmas, Kimberly A. Brown, and Z M. Younossi
Treatment efficacy and safety of low dose seladelpar, a selective PPAR-δ agonist, in patients with primary biliary cholangitis: Twelve-week interim analysis of an international, randomized, dose ranging, phase 2 study., G M. Hirschfield, C L. Bowlus, S A. Harrison, M R. Galambos, B B. Borg, Stuart C. Gordon, N Gitlin, TI Hassanein, J A. Odin, B Bacon, D E. Bernstein, J M. Vierling, A Steinberg, Y J. Choi, M Varga, R Martin, C McWherter, P Boudes, and D Jones
Health outcomes among surveyed patients infected with hepatitis C in the Chronic Hepatitis Cohort Study (CHeCS)., M G. Hofmeister, J Xing, A C. Moorman, Loralee B. Rupp, Stuart C. Gordon, J A. Boscarino, M A. Schmidt, Y H. Daida, Mei Lu, E H. Teshale, S D. Holmberg, and P R. Spradling
Measures of adherence to HCV therapy in a specialty pharmacy setting and association with NON-SVR., S A. Kaurala, M Veve, J Van Lare, J S. Mansour, M Andrews, Kimberly A. Brown, and Susan L. Davis
Safety and efficacy of treatment with once-daily ledipasvir/sofosbuvir (90/400 mg) for 12 weeks in genotype 1 hcv-infected patients with severe renal impairment., Eric Lawitz, Charles S. Landis, Benedict Maliakkal, M Bonacini, G Ortiz-Lasanta, J Zhang, E Mogalian, S De-Oertel, A O. Osinusi, D M. Brainard, John G. McHutchison, Steven L. Flamm, Stuart C. Gordon, and E J. Gane
C-BREEZE 1: Efficacy and safety of ruzasvir 60 mg plus uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis c virus (HCV) genotype (GT)1, 2, 3, 4, or 6 infection., Eric Lawitz, F Poordad, L Anderson, M Vesay, H Liu, D Fernsler, E Asante-Appiah, G J. Hanna, M Robertson, E Barr, J R. Butterton, K V. Knowdley, T I. Hasanein, A K. Sahota, Stuart C. Gordon, and W W. Yeh
Does Hepatitis C eradication lead to improved glucose metabolism, renal and cardiovascular outcomes in diabetic patients?, Jia Li, Stuart C. Gordon, Loralee B. Rupp, Talan Zhang, Sheri Trudeau, S D. Holmberg, A C. Moorman, P R. Spradling, E H. Teshale, J A. Boscarino, M A. Schmidt, Y Daida, and Mei Lu
Impact of sustained virological response on incidence of type 2 diabetes in hepatitis c patients., Jia Li, Talan Zhang, Stuart C. Gordon, Loralee B. Rupp, Sheri Trudeau, S D. Holmberg, A C. Moorman, P R. Spradling, E H. Teshale, J A. Boscarino, M A. Schmidt, Y H. Daida, and Mei Lu
Epidemiologic trends and treatment survival benefits in a US cohort of patients with primary biliary cholangitis (PBC)., Mei Lu, Yueren Zhou, I Haller, R Romanelli, J J. VanWormer, C V. Rodriguez, H Anderson, J A. Boscarino, M A. Schmidt, Y Daida, A K. Sahota, J Vincent, C L. Bowlus, K D. Lindor, T Zhang, Sheri Trudeau, Jia Li, Loralee B. Rupp, and Stuart C. Gordon
Contemporary outcomes and risk factors of acute graft-versus-host disease after liver transplant., J Markus, A Bukannan, B Kashat, and Reena Salgia
The impact of the donor risk index on tumor free survival in patients undergoing liver transplantation with hepatocellular carcinoma., D Moonka, Shunji Nagai, A Harper, and Reena Salgia
The impact of tumor necrosis on tumor free survival in patients undergoing liver transplant with hepatocellular carcinoma: an analysis using the UNOS liver recipient explant pathology form., D Moonka, Reena Salgia, and A M. Harper
An argument for expanding the simultaneous liver and kidney transplant criteria: Validity of the new UNOS allocation policy., Shunji Nagai, M Safwan, Kelly Collins, Michael Rizzari, D Moonka, Kimberly A. Brown, Anita Patel, Atsushi Yoshida, and Marwan S. Abouljoud
